Analysts Anticipate Oncomed Pharmaceuticals Inc (OMED) to Post -$0.31 EPS
Equities analysts expect that Oncomed Pharmaceuticals Inc (NASDAQ:OMED) will announce ($0.31) earnings per share for the current quarter, according to Zacks. Three analysts have issued estimates for Oncomed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.36). Oncomed Pharmaceuticals reported earnings of ($0.64) per share in the same quarter last year, which suggests a positive year over year growth rate of 51.6%. The firm is scheduled to issue its next earnings results on Wednesday, March 14th.
According to Zacks, analysts expect that Oncomed Pharmaceuticals will report full year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.70) to ($1.57). For the next fiscal year, analysts expect that the company will post earnings of ($1.36) per share, with EPS estimates ranging from ($1.69) to ($1.10). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Oncomed Pharmaceuticals.
Oncomed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.13. The firm had revenue of $5.11 million for the quarter, compared to analyst estimates of $6.25 million. During the same quarter in the prior year, the firm earned ($0.77) EPS. The firm’s revenue was down 13.7% compared to the same quarter last year.
A number of institutional investors and hedge funds have recently made changes to their positions in OMED. Marshall Wace North America L.P. purchased a new position in Oncomed Pharmaceuticals during the second quarter valued at approximately $561,000. JPMorgan Chase & Co. grew its position in Oncomed Pharmaceuticals by 1,426.7% during the second quarter. JPMorgan Chase & Co. now owns 83,345 shares of the biopharmaceutical company’s stock valued at $277,000 after purchasing an additional 77,886 shares in the last quarter. AXA purchased a new position in Oncomed Pharmaceuticals during the second quarter valued at approximately $295,000. Ameriprise Financial Inc. grew its position in Oncomed Pharmaceuticals by 42.1% during the second quarter. Ameriprise Financial Inc. now owns 966,995 shares of the biopharmaceutical company’s stock valued at $3,221,000 after purchasing an additional 286,545 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Oncomed Pharmaceuticals by 5.3% during the second quarter. Vanguard Group Inc. now owns 995,646 shares of the biopharmaceutical company’s stock valued at $3,315,000 after purchasing an additional 50,161 shares in the last quarter. 39.38% of the stock is currently owned by hedge funds and other institutional investors.
Oncomed Pharmaceuticals (NASDAQ:OMED) traded down $0.45 during mid-day trading on Tuesday, hitting $3.34. 442,400 shares of the stock were exchanged, compared to its average volume of 209,480. Oncomed Pharmaceuticals has a twelve month low of $2.91 and a twelve month high of $10.89. The firm has a market capitalization of $126.25, a price-to-earnings ratio of -1.76 and a beta of 2.80.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.